Opgepoetst | 3-11-2019
Wageningen Animal Sciences Group makes better TB vaccine
Wageningen animal scientists will coordinate a European project to develop a new vaccine against tuberculosis. The project, which will include thirty partners, starts officially this week. It is worth seventeen million euros and will last five years.
The vaccines that are currently available are not effective in young adults, while it is this group that is worst affected by tuberculosis. The researchers believe they now have the technology available to do something about this.
The consortium plans to develop candidate vaccines and test these on humans. Pharmaceutical companies will then develop the vaccines further so that they can be brought on the market.
The demand for new TB vaccines is growing. The increase of HIV and Aids in developing countries has led to an increase in the incidence of TB, and at the same time doctors are encountering resistant strains more often. Sooner or later these will also show up in Europe.
Weekblad voor Wageningen UR, 19 februari 2004.